Views: 1,306 | Downloads:
25
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Comparison of Norgestrel- Versus Cyproterone Acetate-Containing Hormone Replacement Therapy on Lipid -Lipoprotein Metabolism
Panyakhamlerd K 
,
Limpaphayom K ,
Taechakraichana N ,
Chaikittisilpa S ,
Pasatrat S ,
Pojanasopanakun S
,
Limpaphayom K ,
Taechakraichana N ,
Chaikittisilpa S ,
Pasatrat S ,
Pojanasopanakun S To compare the effects on the lipid profile of estradiol valerate with norgestrel to a regimen
of estradiol valerate with cyproterone acetate. Sixty-four healthy women in their perimenopause
or early postmenopause, aged between 40-55 years, were randomized to one of the two 21-day
sequential regimens: estradiol valerate 2 mg/day for 21 days and combined with either norgestrel
0.5 mg/day or cyproterone acetate 1 mg/day from day 12 to 21, with 7 days of drug-free interval,
for 12 cycles. Lipid profiles were followed at baseline, 6 and 12 cycles. Sixty-one subjects com-
pleted the study, 30 in the norgestrel group and 31 in the cyproterone group. During 12 cycles of
study, serum HDL cholesterol levels decreased significantly in the norgestrel group (p
of estradiol valerate with cyproterone acetate. Sixty-four healthy women in their perimenopause
or early postmenopause, aged between 40-55 years, were randomized to one of the two 21-day
sequential regimens: estradiol valerate 2 mg/day for 21 days and combined with either norgestrel
0.5 mg/day or cyproterone acetate 1 mg/day from day 12 to 21, with 7 days of drug-free interval,
for 12 cycles. Lipid profiles were followed at baseline, 6 and 12 cycles. Sixty-one subjects com-
pleted the study, 30 in the norgestrel group and 31 in the cyproterone group. During 12 cycles of
study, serum HDL cholesterol levels decreased significantly in the norgestrel group (p
Download:
PDF